[
  {
    "ts": "2025-10-10T23:11:00+00:00",
    "headline": "AstraZeneca Strikes Drug-Pricing Deal With Trump Administration",
    "summary": "The agreement, which entails offering “most-favored nation” pricing, follows Pfizer’s deal to reduce prices for its drugs sold in the Medicaid program and through a direct-purchasing service to be branded TrumpRx.",
    "url": "https://www.wsj.com/health/pharma/astrazeneca-to-ink-drug-pricing-deal-with-trump-administration-457fe317?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "38d99a4e-52dc-3430-91f8-72371d3fe13b",
      "content": {
        "id": "38d99a4e-52dc-3430-91f8-72371d3fe13b",
        "contentType": "STORY",
        "title": "AstraZeneca Strikes Drug-Pricing Deal With Trump Administration",
        "description": "",
        "summary": "The agreement, which entails offering “most-favored nation” pricing, follows Pfizer’s deal to reduce prices for its drugs sold in the Medicaid program and through a direct-purchasing service to be branded TrumpRx.",
        "pubDate": "2025-10-10T23:11:00Z",
        "displayTime": "2025-10-10T23:11:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/38d99a4e-52dc-3430-91f8-72371d3fe13b/astrazeneca-strikes.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/136a73a93267817721227ea1d6f32880",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qyEzV.mDqEAjOUTVq7H1Zw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/136a73a93267817721227ea1d6f32880.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jeXXbtEspTVwv6Yd9EF12Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/136a73a93267817721227ea1d6f32880.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/astrazeneca-to-ink-drug-pricing-deal-with-trump-administration-457fe317?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AZN"
            },
            {
              "symbol": "AZNCF"
            },
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-10T21:58:15+00:00",
    "headline": "Trump Announces AstraZeneca Drug Price Cuts for Tariff Reprieve",
    "summary": "“AstraZeneca, the largest pharmaceutical manufacturer in the United Kingdom, is committing to offer Americans major discounts on their vast catalog of prescription drugs,” Trump said Friday in the Oval Office, where he was joined by AstraZeneca Chief Executive Officer Pascal Soriot.  The deal — similar to a pact announced last week by Pfizer Inc. — will see AstraZeneca slash what it charges for its medicines in exchange for three years of relief from threatened tariffs on the pharmaceutical industry.",
    "url": "https://finance.yahoo.com/news/astrazeneca-said-reach-drug-price-173237962.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "e26d9a63-8ee8-3d9b-8c38-99a7e4c67b65",
      "content": {
        "id": "e26d9a63-8ee8-3d9b-8c38-99a7e4c67b65",
        "contentType": "STORY",
        "title": "Trump Announces AstraZeneca Drug Price Cuts for Tariff Reprieve",
        "description": "",
        "summary": "“AstraZeneca, the largest pharmaceutical manufacturer in the United Kingdom, is committing to offer Americans major discounts on their vast catalog of prescription drugs,” Trump said Friday in the Oval Office, where he was joined by AstraZeneca Chief Executive Officer Pascal Soriot.  The deal — similar to a pact announced last week by Pfizer Inc. — will see AstraZeneca slash what it charges for its medicines in exchange for three years of relief from threatened tariffs on the pharmaceutical industry.",
        "pubDate": "2025-10-10T21:58:15Z",
        "displayTime": "2025-10-10T21:58:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/bloomberg_holding_pen_162/09dcc2b922626904fa68ba54f01633a1",
          "originalWidth": 2000,
          "originalHeight": 1333,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ylSqQ4CFDfFlfY4S5IB23A--~B/aD0xMzMzO3c9MjAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/bloomberg_holding_pen_162/09dcc2b922626904fa68ba54f01633a1.cf.webp",
              "width": 2000,
              "height": 1333,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/eUV1h7z0YK8Uyk9zge9Iww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_holding_pen_162/09dcc2b922626904fa68ba54f01633a1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/company"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/astrazeneca-said-reach-drug-price-173237962.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/astrazeneca-said-reach-drug-price-173237962.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-10T16:19:00+00:00",
    "headline": "Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going.",
    "summary": "The recent cavalcade of biotech deals continued Friday morning, when  Bristol Myers Squibb  said it had agreed to pay $1.5 billion to acquire Orbital Therapeutics, an early-stage, privately held biotech designing RNA-based medicines.  Its lead program, a potential treatment for autoimmune conditions called OTX-201, isn’t expected to enter human trials until next year.  The Orbital deal is Bristol’s largest since February 2024, when it closed a $4.1 billion acquisition of RayzeBio, a cancer-focused biotech.",
    "url": "https://www.barrons.com/articles/bristol-myers-squibb-orbital-therapeutics-9cbc5536?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "e9d415ae-bc30-3141-a6cb-2286f58343a3",
      "content": {
        "id": "e9d415ae-bc30-3141-a6cb-2286f58343a3",
        "contentType": "STORY",
        "title": "Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going.",
        "description": "",
        "summary": "The recent cavalcade of biotech deals continued Friday morning, when  Bristol Myers Squibb  said it had agreed to pay $1.5 billion to acquire Orbital Therapeutics, an early-stage, privately held biotech designing RNA-based medicines.  Its lead program, a potential treatment for autoimmune conditions called OTX-201, isn’t expected to enter human trials until next year.  The Orbital deal is Bristol’s largest since February 2024, when it closed a $4.1 billion acquisition of RayzeBio, a cancer-focused biotech.",
        "pubDate": "2025-10-10T16:19:00Z",
        "displayTime": "2025-10-10T16:19:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/e9d415ae-bc30-3141-a6cb-2286f58343a3/bristol-myers-squibb-buys.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/8f8bbf75eff3be3b648bed5cb28cacca",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bf402q.1QSge2in2qsVa4w--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/8f8bbf75eff3be3b648bed5cb28cacca.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9_PIBaIStwamvAA7QXT2sQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/8f8bbf75eff3be3b648bed5cb28cacca.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/bristol-myers-squibb-orbital-therapeutics-9cbc5536?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "GMAB"
            },
            {
              "symbol": "GNMSF"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "AKRO"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-10T10:45:00+00:00",
    "headline": "2 Pharmaceutical Stocks That Look Like No-Brainer Buys Right Now",
    "summary": "Ongoing developments make these companies look attractive.",
    "url": "https://www.fool.com/investing/2025/10/10/2-pharmaceutical-stocks-that-look-like-no-brainer/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "f15c5d9f-2b47-3f0c-b8e3-322b4975e1ff",
      "content": {
        "id": "f15c5d9f-2b47-3f0c-b8e3-322b4975e1ff",
        "contentType": "STORY",
        "title": "2 Pharmaceutical Stocks That Look Like No-Brainer Buys Right Now",
        "description": "",
        "summary": "Ongoing developments make these companies look attractive.",
        "pubDate": "2025-10-10T10:45:00Z",
        "displayTime": "2025-10-10T10:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/dd4f60345a730dc8ffef26a2f5028466",
          "originalWidth": 720,
          "originalHeight": 441,
          "caption": "LLY Revenue (Quarterly YoY Growth) Chart",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oIZf_avflLIrCf6fc.Cxdg--~B/aD00NDE7dz03MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/dd4f60345a730dc8ffef26a2f5028466.cf.webp",
              "width": 720,
              "height": 441,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/eBGRnKS3Ji0nUOyjP_ORug--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/dd4f60345a730dc8ffef26a2f5028466.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/10/10/2-pharmaceutical-stocks-that-look-like-no-brainer/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-pharmaceutical-stocks-look-no-104500789.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-10T09:32:14+00:00",
    "headline": "Pharma R&D set to endure despite rising MFN costs",
    "summary": "MFN-driven drug price reductions are unlikely to impact pharma R&D spending.",
    "url": "https://www.clinicaltrialsarena.com/features/pharma-rd-set-to-endure-despite-rising-mfn-costs/",
    "source": "Clinical Trials Arena",
    "provider": "yfinance",
    "raw": {
      "id": "00657a72-64c4-3dad-8d88-c868a36d2672",
      "content": {
        "id": "00657a72-64c4-3dad-8d88-c868a36d2672",
        "contentType": "STORY",
        "title": "Pharma R&D set to endure despite rising MFN costs",
        "description": "",
        "summary": "MFN-driven drug price reductions are unlikely to impact pharma R&D spending.",
        "pubDate": "2025-10-10T09:32:14Z",
        "displayTime": "2025-10-10T09:32:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/clinical_trials_arena_396/11e91e0cbbd51d96e73420dbd8096ad3",
          "originalWidth": 1440,
          "originalHeight": 711,
          "caption": "While MFN will see US drug prices reduced to match other countries",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bUbHNwbstH91S7e34xEM9g--~B/aD03MTE7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/11e91e0cbbd51d96e73420dbd8096ad3.cf.webp",
              "width": 1440,
              "height": 711,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/D7GICkzU9XfPV8Llp_0oGw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/clinical_trials_arena_396/11e91e0cbbd51d96e73420dbd8096ad3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Clinical Trials Arena",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.clinicaltrialsarena.com/features/pharma-rd-set-to-endure-despite-rising-mfn-costs/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pharma-r-d-set-endure-093214296.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-10T07:18:00+00:00",
    "headline": "Here's How This Pharmaceutical Giant Is Protecting Itself From President Trump's Tariffs. Should It Matter to Investors?",
    "summary": "A new deal with the White House could lead to a new sales channel that bypasses health insurance companies.",
    "url": "https://www.fool.com/investing/2025/10/10/heres-how-this-pharmaceutical-giant-is-protecting/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "48c41240-1625-317e-8e82-f0cf80f396f6",
      "content": {
        "id": "48c41240-1625-317e-8e82-f0cf80f396f6",
        "contentType": "STORY",
        "title": "Here's How This Pharmaceutical Giant Is Protecting Itself From President Trump's Tariffs. Should It Matter to Investors?",
        "description": "",
        "summary": "A new deal with the White House could lead to a new sales channel that bypasses health insurance companies.",
        "pubDate": "2025-10-10T07:18:00Z",
        "displayTime": "2025-10-10T07:18:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/a44a32f42dd5b96e79bf01ed0a618ed7",
          "originalWidth": 1024,
          "originalHeight": 652,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HkwQ83tODc4V3JD2R.vLAQ--~B/aD02NTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/a44a32f42dd5b96e79bf01ed0a618ed7.cf.webp",
              "width": 1024,
              "height": 652,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ver741_9Xg.ksnvqvi5UVA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/a44a32f42dd5b96e79bf01ed0a618ed7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/10/10/heres-how-this-pharmaceutical-giant-is-protecting/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-pharmaceutical-giant-protecting-itself-071800819.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]